- Dual Recognition Underscores Binah’s Unmatched Commitment to Leadership and Operational Excellence -NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, June 5th by Binah Capital Group (Nasdaq: BCG), please note that the last sentence of the first paragraph has been revised. The corrected release follows: Binah Capital Group, Inc. (“Binah Capital”) (NASDAQ: BCG), a financial services enterprise supporting the growth of independent financial advisors, today a ...

- Dual Recognition Underscores Binah’s Unmatched Commitment to Leadership and Operational Excellence -NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah Capital”) (NASDAQ: BCG), a financial services enterprise supporting the growth of independent financial advisors, today announced that PKS Investments (“PKS”), a Binah Capital Group company, has been named a finalist in two categories for the prestigious 2025 Wealth Management Industry Awards (“The Wealthies”). The categories are ...

- Grew Total Revenue 18% Year-over-Year to $49 Million - - Assets Under Management (“AuM”) Increased 3% Year-over-Year to $26 Billion - - Net Income of $1 Million - - Increased EBITDA1 to $2.2 Million from $(0.0) Million in the Prior Year - NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advi ...

收入和利润（同比环比） - 2025年第一季度总营收同比增长18%，达到4900万美元[1][6] - 净利润为100万美元，上年同期净亏损160万美元[6][19] - EBITDA从上年的0美元增至220万美元[1][7][21] - 毛利润为860万美元，上年同期为780万美元[6] - 2025年第一季度总营收为4893.6万美元，2024年同期为4144.9万美元[19] 成本和费用（同比环比） - 总运营费用为700万美元，上年同期为1000万美元[6] 其他财务数据 - 管理资产（AuM）同比增长3%，达到260亿美元[1][6] - 总咨询和经纪资产同比增长3%，达到260亿美元[6] - 截至2025年3月31日，公司现金及现金等价物为900万美元，未偿还长期债务为2500万美元[8] - 2025年3月31日总资产为6.7877亿美元，2024年12月31日为6.6677亿美元[17]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40742 Binah Capital Group, Inc. (Exact name of registrant as specified in its charter) Delaware 88-3276689 (State or ...

About Binah Capital Group Binah Capital Group ("Binah Capital," "Binah" or the "Company") is a financial services enterprise that owns and operates a network of industry-leading firms that empower independent financial advisors. As a national broker-dealer aggregator, Binah specializes in delivering value through its innovative hybrid-friendly model, making it an optimal platform for RIAs navigating today's complex financial landscape. Binah's portfolio companies are built to help advisors run, manage, and ...

- Will Contribute to Development and Implementation of Long-Term Business Strategy -NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah Capital”) (NASDAQ: BCG), a leading financial services enterprise that owns and operates a network of firms empowering independent financial advisors, today welcomed Ryan Marcus as its new Chief Business Development and Engagement Officer. In his new role, Mr. Marcus will work closely with Binah Capital’s broker-dealers, including PKS Investments, Ca ...

文章核心观点 - 强生公司旗下杨森-西拉格国际宣布2b期SunRISe - 1研究第4组评估TAR - 200治疗特定膀胱癌患者的首批结果，显示TAR - 200在该患者群体中有潜力，有望成为手术的有效替代方案 [1] 分组1：研究结果 - TAR - 200治疗卡介苗无反应、高危非肌肉浸润性膀胱癌（HR - NMIBC）仅乳头状疾病患者，6个月和9个月无病生存率（DFS）分别为85.3%（95%置信区间[CI]，71.6 - 92.7）和81.1%（95% CI，66.7 - 89.7） [1] - 高分级Ta和T1疾病患者中，6个月DFS分别为85.7%（95% CI，66.3 - 94.4）和84.7%（95% CI，59.7 - 94.8），9个月分别为82.1%（95% CI，62.3 - 92.1）和79.4%（95% CI，54.0 - 91.7） [1] - 中位随访12.8个月时，94.2%的患者避免了根治性膀胱切除术 [1] - 9个月时无进展生存率和总生存率分别为95.6%（95% CI，83.5 - 98.9）和98%（95% CI，86.4 - 99.7） [1] 分组2：药物安全性 - 52名入组患者中，TAR - 200单药治疗的安全性与先前研究一致，无新的安全信号 [1][2] - 大多数治疗相关不良事件（TRAEs）为低级别且迅速缓解，中位持续时间为3.7周 [2] - 常见TRAEs包括排尿困难（40.4%）、尿频（30.8%）和尿急（26.9%） [2] - 13.5%的患者发生≥3级TRAEs，最常见为膀胱疼痛（3.8%） [2] - 3名患者（5.8%）经历严重TRAEs，4名（7.7%）因TRAEs停药，无治疗相关死亡报告 [2] 分组3：行业背景 - 欧洲膀胱癌发病率全球最高，2022年近25万人确诊，较2020年增加10% [2] - 尽管有进展，但40多年来膀胱癌标准治疗基本未变，卡介苗初始治疗无效的患者治疗选择有限 [2] 分组4：TAR - 200介绍 - TAR - 200是一种研究性膀胱内吉西他滨释放系统，旨在向膀胱持续、局部释放吉西他滨 [3] - 其安全性和有效性正在SunRISe - 1、SunRISe - 3和SunRISe - 5的非肌肉浸润性膀胱癌（NMIBC）患者以及SunRISe - 4的肌肉浸润性膀胱癌（MIBC）患者中进行2期和3期研究评估 [3] 分组5：SunRISe - 1第4组研究介绍 - SunRISe - 1（NCT04640623）是一项正在进行的2b期、随机、开放标签、多中心研究，评估TAR - 200治疗卡介苗无反应、不适合或选择不进行根治性膀胱切除术的HR - NMIBC患者的疗效和安全性 [3] - 第4组专门招募仅乳头状疾病患者，采用TAR - 200单药治疗，主要终点是DFS率，关键次要终点包括安全性和耐受性 [3] 分组6：HR - NMIBC介绍 - HR - NMIBC是一种非侵入性膀胱癌，比低风险NMIBC更易复发、扩散至膀胱上皮以外并进展为MIBC [4] - HR - NMIBC占NMIBC患者的15 - 44%，特点为高分级、肿瘤大、多肿瘤和原位癌（CIS） [4] - 卡介苗治疗失败的HR - NMIBC患者目前推荐根治性膀胱切除术，肌肉浸润进展前进行手术，癌症特异性生存率超90% [4] 分组7：强生公司介绍 - 强生公司认为健康就是一切，凭借医疗创新实力，致力于构建一个复杂疾病可预防、治疗和治愈的世界，通过创新药物和医疗技术专长，在医疗解决方案全领域进行创新 [5]

NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. ("Binah" or "the Company") (NASDAQ:BCG, BCGWW)), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, proudly announces that its Chief Financial Officer ("CFO"), David Shane, has been named one of the Top 5 Wealth Management CFOs by Wealth Solutions Report in their annual "CFO 5" list. This prestigious recognition highlights CFOs who have demonstrate ...

NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. ("Binah" or “the Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, proudly announces that its Chief Financial Officer (“CFO”), David Shane, has been named one of the Top 5 Wealth Management CFOs by Wealth Solutions Report in their annual "CFO 5" list. This prestigious recognition highlights CFOs who have demonstrate ...